Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma

(MedPage Today) -- Treating high-risk smoldering multiple myeloma with single-agent daratumumab (Darzalex) delayed progression to active myeloma, according to findings from the phase III AQUILA trial presented at the American Society of Hematology...